Geode Capital Management
MRTX

Geode Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Geode Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-980,029
Closed -$57.6M – 4711
2023
Q4 		$57.6M Buy
980,029
+98,803
+11% +$5.55M 0.01% 1252
2023
Q3 		$38.4M Buy
881,226
+116,743
+15% +$4.17M ﹤0.01% 1406
2023
Q2 		$27.6M Buy
764,483
+29,195
+4% +$1.2M ﹤0.01% 1642
2023
Q1 		$27.3M Buy
735,288
+27,943
+4% +$1.26M ﹤0.01% 1596
2022
Q4 		$32M Buy
707,345
+51,395
+8% +$3.33M ﹤0.01% 1455
2022
Q3 		$45.8M Buy
655,950
+8,900
+1% +$659K 0.01% 1140
2022
Q2 		$43.4M Buy
647,050
+8,721
+1% +$555K 0.01% 1221
2022
Q1 		$52.5M Buy
638,329
+22,376
+4% +$2.29M 0.01% 1222
2021
Q4 		$90.4M Buy
615,953
+55,104
+10% +$8.56M 0.01% 900
2021
Q3 		$99.2M Sell
560,849
-8,330
-1% -$1.34M 0.01% 803
2021
Q2 		$91.9M Sell
569,179
-185,457
-25% -$29.8M 0.01% 839
2021
Q1 		$129M Buy
754,636
+55,901
+8% +$11.1M 0.02% 646
2020
Q4 		$153M Buy
698,735
+123,533
+21% +$26.7M 0.03% 546
2020
Q3 		$95.5M Buy
575,202
+3,803
+0.7% +$520K 0.02% 622
2020
Q2 		$65.2M Buy
571,399
+62,345
+12% +$6.05M 0.01% 748
2020
Q1 		$39.1M Buy
509,054
+67,561
+15% +$6.06M 0.01% 894
2019
Q4 		$56.9M Buy
441,493
+11,369
+3% +$1.1M 0.01% 859
2019
Q3 		$33.5M Buy
430,124
+17,323
+4% +$1.63M 0.01% 1127
2019
Q2 		$42.5M Buy
412,801
+41,098
+11% +$3.2M 0.01% 961
2019
Q1 		$27.2M Buy
371,703
+57,485
+18% +$3.91M 0.01% 1210
2018
Q4 		$13.3M Buy
314,218
+25,293
+9% +$1.01M ﹤0.01% 1577
2018
Q3 		$13.6M Buy
288,925
+17,182
+6% +$957K ﹤0.01% 1700
2018
Q2 		$13.4M Buy
271,743
+87,337
+47% +$3.3M ﹤0.01% 1644
2018
Q1 		$5.66M Hold
184,406
– – ﹤0.01% 2162
2017
Q4 		$3.37M Buy
184,406
+14,721
+9% +$228K ﹤0.01% 2459
2017
Q3 		$1.99M Buy
169,685
+67,621
+66% +$391K ﹤0.01% 2755
2017
Q2 		$372K Sell
102,064
-16,924
-14% -$64.8K ﹤0.01% 3458
2017
Q1 		$618K Buy
118,988
+9,726
+9% +$53.3K ﹤0.01% 3229
2016
Q4 		$518K Buy
109,262
+2,340
+2% +$12.7K ﹤0.01% 3258
2016
Q3 		$706K Sell
106,922
-2,917
-3% -$15.5K ﹤0.01% 3115
2016
Q2 		$599K Buy
109,839
+7,711
+8% +$123K ﹤0.01% 3145
2016
Q1 		$2.19K Sell
102,128
-2,520
-2% -$56.4K ﹤0.01% 2394
2015
Q4 		$3.31M Buy
104,648
+11,148
+12% +$394K ﹤0.01% 2157
2015
Q3 		$3.22M Buy
93,500
+80,159
+601% +$2.42M ﹤0.01% 2131
2015
Q2 		$419K Buy
13,341
+1,414
+12% +$41.7K ﹤0.01% 3280
2015
Q1 		$349K Buy
+11,927
New +$280K ﹤0.01% 3348

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Geode Capital Management's MRTX Position: Q1 2024 in Review

Geode Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 980,029 shares — an estimated $57.6M sold.

Geode Capital Management first reported a position in MRTX in Q1 2015 and held it in 36 quarters. The position peaked at $153M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Geode Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Geode Capital Management sold 980,029 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $57.6M.
  • Geode Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2015 and held it in 36 quarters.
  • Geode Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $153M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Geode Capital Management's 13F filing for Q1 2024, filed 13 May 2024.